PlainPharmaWatch

CMS Open Payments · Tool

Zavation Medical Products, LLC vs restor3d, inc.

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Zavation Medical Products, LLC has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 1,183, versus 486 for the other company. Its single largest recorded recipient represents 27.8% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Zavation Medical Products, LLC
HHI 1,183 · top recipient 27.8%
Ranked #954 of 1,838 companies by HHI
restor3d, inc.
HHI 486 · top recipient 12.4%
Ranked #1,299 of 1,838 companies by HHI

Payment Overview

Total Payments
$1.6M
% of Industry
0.0%
Transactions
562
Avg per Transaction
$2.9K
Recipients
560
Avg per Recipient
$2.9K
Payment Types
4
Top Payment Type
Consulting Fee
Company B

restor3d, inc.

Total Payments
$1.6M
% of Industry
0.0%
Transactions
1,071
Avg per Transaction
$1.5K
Recipients
1,071
Avg per Recipient
$1.5K
Payment Types
4
Top Payment Type
Consulting Fee

Highlighted values indicate the higher figure for each metric.

Total payments compared

Zavation Medical Products, LLC vs restor3d, inc. - total reported payments in CMS Open Payments PY2024

Zavation Medical Products,…$1.6Mrestor3d, inc.$1.6M

General Payment Types Breakdown

Category shares use each company's General Payments total, not the all-tracks (General + Research + Ownership) hero figure.

Zavation Medical Products, LLC

Consulting Fee $323.2K

46.4%

Royalty or License $291.6K

41.9%

Travel and Lodging $53.4K

7.7%

Food and Beverage $28.4K

4.1%

restor3d, inc.

Consulting Fee $1.3M

82.0%

Royalty or License $148.6K

9.3%

Travel and Lodging $92.8K

5.8%

Food and Beverage $46.5K

2.9%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Zavation Medical Products, LLC

  1. 1

    RYAN DENHAESE

    $193,745.39 · 46 txns

  2. 2

    MOHAMMAD ETMINAN

    $100,000.00 · 10 txns

  3. 3

    BABAJIDE OGUNSEINDE

    $56,437.74 · 21 txns

  4. 4

    KENNETH STRENGE

    $52,918.09 · 9 txns

  5. 5

    JUSTIN OWEN

    $30,569.12 · 14 txns

restor3d, inc.

  1. 1

    WOLFGANG FITZ

    $198,856.77 · 13 txns

  2. 2

    SCOTT BALL

    $179,876.71 · 20 txns

  3. 3

    JOSE RODRIGUEZ

    $122,764.85 · 4 txns

  4. 4

    William Kurtz

    $92,356.88 · 15 txns

  5. 5

    JOHN ELLINGTON

    $90,410.12 · 25 txns

Summary Comparison

Metric Zavation Medical Products, LLC restor3d, inc.
Total Payments $1.6M $1.6M
% of Industry Total 0.0% 0.0%
Transaction Count 562 1,071
Avg per Transaction $2.9K $1.5K
Recipient Count 560 1,071
Avg per Recipient $2.9K $1.5K
Payment Type Count 4 4
Top Payment Type Consulting Fee Consulting Fee

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.